Daily Protein Science

Tata Motors on Thursday unveiled a state-of-the-art electric vehicle technology ‘Ziptron’, which will power a range of aspirational Tata electric cars, starting with a new launch in the fourth quarter of the current financial year.

The new technology will form the basis of Tata Motors’ future EVs, and with it the auto major will ramp up its presence in the electric vehicle segment. The new technology, branded ‘Ziptron’, will first be used on a model set for launch in early 2020.
“Ziptron, a soon to be introduced EV powertrain technology, is a building block towards Tata Motors’ consistent strive for commonality, to drive economies of scale and to make new technologies affordable for the Indian consumers. It embodies distinctive characteristics: efficient high voltage system, zippy performance, long range, fast charging capability, battery with warranty of 8 years, and adherence to IP67 standard,” Tata Motors stated in a release.
Tata Motors says Ziptron has been developed keeping Indian climatic and traffic conditions in mind, and also addresses typical EV buyers' concerns of performance, range and safety.
While Tata Motors has not revealed final specifications as yet, company spokespersons announced that cars built with Ziptron will have a “minimum range of 250km” and will support fast charging. The battery pack comprises lithium-ion cells and features liquid cooling to maintain the ideal operating temperature. The battery pack comes in a high-strength steel casing and boasts an IP67 rating, assuring highest standards for waterproofing and dust protection. Tata Motors will offer a standard eight-year warranty on the battery pack and motor.
The high-voltage 300V-plus permanent magnet synchronous electric motor also promises to be leagues ahead of the 72V AC induction-type motor on the Tigor EV in performance and output. The motor will come mated to a single-ratio transmission that has been optimised for Indian traffic. Ziptron cars will also feature drive modes to give drivers the option to maximise range or enhance performance.
Speaking at the launch, Guenter Butschek, CEO and MD, Tata Motors said the state-of-art technology brand `Ziptron’ has been designed in-house while utilising the group’s global engineering network.
“At the heart of our future EV line-up, this technology will deliver a thrilling driving experience to our customers aspiring to go-green. Rigorously tested across 1 million kms, Ziptron technology is well proven, advanced and reliable. With this technology, we hope to usher in a new wave of eMobility in India and accelerate faster adoption of EVs, supporting the government’s vision,” he added.
Connected technology will also be part of the package on Tata’s upcoming electric cars giving buyers remote access to vehicle health, status and location reports.
Ziptron technology comprises a highly efficient permanent magnet AC motor providing superior performance on demand. It also offers best in industry dust and water proof battery system meeting IP67 standards. Further, Ziptron utilises smart regenerative braking to charge the battery while on the drive, the company stated.
Along with Ziptron, Tata Motors also rolled out the Ziptron Freedom 2.0 campaign. This campaign aims at highlighting how this technology breaks existing barriers and provides freedom from pollution, addresses range anxiety, and offers electrifying driving performance. Source: https://www.domain-b.com/

Read More........→July 15, 2020 Categories: Auto,India,Science-Technology

There was, however, no further information on when this vaccine would enter commercial production stage

Moscow: Russia has become the first nation to complete clinical trials of Covid-19 vaccine on humans, and the results have proven the medication's effectiveness, the media reported on Sunday.

Chief researcher Elena Smolyarchuk, who heads the Center for Clinical Research on Medications at Sechenov University, told Russian news agency TASS on Sunday that the human trials for the vaccine have been completed at the university and they will be discharged soon.

"The research has been completed and it proved that the vaccine is safe. The volunteers will be discharged on July 15 and July 20," Smolyarchuk was quoted as saying in the report.

Commercial production

There was, however, no further information on when this vaccine would enter commercial production stage.

Russia had allowed clinical trials of two forms of a potential Covid-19 vaccine developed by the Gamaleya National Research Center for Epidemiology and Microbiology on June 18.

The first vaccine, in the form of a solution for intramuscular administration, was carried out at the Burdenko Military Hospital.

Another vaccine, in the form of a powder for the preparation of a solution for intramuscular administration, was carried out at Sechenov First Moscow State Medical University.

How Sechenov University did it?

The first stage of research on the vaccine at Sechenov University involved a group of 18 volunteers and the second group involved 20 volunteers.

After vaccination, all volunteers were expected to remain in isolation in a hospital for 28 days.

Earlier, results of the COVID-19 vaccine tests performed on a group of volunteers in Russia showed that they were developing immunity to the coronavirus.

"The data obtained by the Gamalei National Research Center for Epidemiology and Microbiology, proves that volunteers of the first and second groups are forming an immune response after injections of the vaccine against the coronavirus," according to an earlier statement from the Russian Defense Ministry.

21 vaccines under key trials

There are at least 21 vaccines currently under key trials, according to the World Health Organisation (WHO).

Russia has reported 719,449 cases and 11,188 deaths to date.

The overall number of global COVID-19 cases was nearing 12.7 million, while the deaths have increased to more than 564,000, according to Johns Hopkins University in the US.

As of Sunday morning, the total number of cases stood at 12,681,472, while the fatalities rose to 564,420.

The US accounted for the world's highest number of infections and fatalities at 3,245,158 and 134,764. Brazil came in the second place with 1,839,850 infections and 71,469 deaths. Source: https://ummid.com/